In the news
FDA approves new MS treatment regimen developed at Wayne State University
January 30, 2014
Global research overseen by and conducted at the Wayne State University School of Medicine will immediately change the treatment regimen of millions of multiple sclerosis patients around the world. The U.S. Food and Drug Administration Tuesday approved a new drug application that calls for the injection of Copaxone at a higher dose, but fewer times per week for patients with relapsing forms of multiple sclerosis. "The availability of three-times-a-week Copaxone 40 mg/mL is a significant advancement for patients as they now have the option of effective and safe treatment with the drug, while reducing the number of injections by 60 percent," said Omar Khan, M.D., professor and chair of neurology at the Wayne State University School of Medicine. "Patients in the United States can now benefit from an improved dosing regimen without compromising the known benefits of Copaxone." The study was published in the Annals of Neurology, a leading clinical neuroscience journal and the official publication of the American Neurological Association. The Wayne State University MS Center is considered amongst the five largest MS centers in the country, with more than 4,000 patients. Dr. Khan said Wayne State University is now poised to submit a multi-center study to the National Institute of Neurological Disorders and Stroke later this year to take the concept a step further, even beyond the current dosing regimen.